Additionally, CDCP1, DUXAP8, SUCLG2P2, and MT1DP are recognized as prognostic indicators, offering insights into clinical outcomes and supporting tailored therapeutic approaches for CRC management. Here, DUXAP8 is linked to colorectal carcinoma.